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Abstract
OBJECTIVES To evaluate availability issues of 
medicinal products in Malta and to identify therapeutic 
groups for which no products are authorised or available.
METHOD An extensive review of the Malta Medicines 
List (March 2015) was carried out and key factors affecting 
availability were identified.
KEY FINDINGS An estimated average of 62% of 
authorised medicinal products are actually placed on the 
Maltese market and the lowest availability rates recorded 
were for authorisations made via Article 126(a) of Directive 
2001/83/EC.
CONCLUSION Smaller European member states 
such as Malta share availability issues as regards medicinal 
products and initiatives should be implemented to prevent 
such situations from impacting public health. 
KEYWORDS ATC Codes, Availability, Malta Medicines 
List, Medicinal Products
Introduction
The market of medicinal products in the European Union is 
a highly regulated area. Medicinal products are regulated 
differently compared to other products and placement 
of these products on the market is not solely the 
responsibility of the manufacturer. Market authorisations 
are granted by the regulatory authorities of member states 
or the European Commission (EC) after being assessed by 
relevant expertise. Such authorisations can however only 
be granted after the manufacturer has applied for them, 
which may lead to situations where medicinal products are 
not equally available in all member states.1 
Unavailability of some medicinal products is a threat to 
public health and welfare since it may create problems for 
patients, healthcare professionals and also governments. 
Consequences for patients will depend on the severity of 
their disease or condition and the availability of therapeutic 
alternatives. Availability of human medicinal products on 
small markets such as Malta is a public health concern 
which requires adequate attention. The aim of the study 
was to evaluate availability issues of medicinal products 
in Malta and to identify therapeutic groups for which no 
products are authorised or available.
Method
This study was divided into three phases. In phase 1 review 
of the Malta Medicines List (March 2015) issued by the 
Medicines Authority (MA) outlining all medicinal products 
authorised in Malta was carried out. The products in 
this list were re-grouped according to the Anatomical 
Therapeutic Chemical (ATC) classification system, a system 
of alphanumeric codes developed by the World Health 
Organization for classification of drugs and other medicinal 
products. After grouping them according to their ATC 
codes, the products were further sub-divided according 
to their route of authorisation, namely national marketing 
authorisations, authorisations made via Article 126(a) of 
Directive 2001/83/EC2 and parallel import licenses. In 
phase 2 Maltese wholesale dealers were consulted to 
develop a database of medicinal products licensed with 
the MA that are subsequently placed on the local market, 
and phase 3 involved identification of discontinuities in 
the availability of medicinal products. Reasons why these 
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products were not marketed were identified and tabulated 
and statistical analysis of the outcomes was performed. The 
length and duration of each phase varied according to the 
response rate from marketing authorisation holders and 
wholesale dealers. Each phase of the study was carried out 
with the assistance and advice of the staff at the Licensing 
Directorate at the MA. 
Results
On average 62% of the products authorised in the Malta 
Medicines List are subsequently placed on the market and 
made available to patients. The average availability rate 
for all products pertaining to ATC Code A ‘Alimentary Tract 
and Metabolism’ was 49%. Several groups in this category 
were found to have significantly low availability rates. In 
the category of products for ‘bile and liver therapy’ (Group 
A05), five products were licensed and only two of these 
have been placed on the market. Similarly, for ‘anti-obesity 
preparations’ (Group A08) only one product is licensed 
and marketed locally. For ‘digestives, including enzymes’ 
(Group A09), only two authorised products were identified, 
out of which only one is marketed. For ‘tonics’ (Group 
A13), three out of four products are available in Malta, 
and no products have been authorised for systemic use 
with respect to ‘anabolic agents’ (Group A14), For Group 
A15, ‘appetite stimulants’, one product is authorised and 
subsequently marketed and for ‘other alimentary tract 
and metabolism products’ (Group A16) two products have 
been authorised, however none have been placed on the 
local market.
The average availability rate for products pertaining to 
ATC code B ‘Blood and Blood-Forming Organs’ was 44%, 
representing the lowest average availability rate for 
licensed medicines recorded for all ATC codes. Only one 
group within this therapeutic category was considered at 
risk of availability problems namely ‘other haematological 
agents’ (Group B06) where three products are licensed but 
only two have been placed on the market. The average 
availability rate for products in ATC code C ‘Cardiovascular 
System’ was calculated to be 57% which is higher compared 
to the first two therapeutic categories. Only Group C04 for 
‘peripheral vasodilators’ was considered to pose a potential 
availability problem as only two products are licensed in 
this category and both are marketed locally. However, at 
the time the study was carried out one of these products 
was experiencing a temporary availability problem and 
therefore only one medicinal product was considered 
available in Malta for this therapeutic group.
For ATC Code D, ‘Dermatological Products’, average 
availability rate was 69%. For both ‘preparations for 
treatment of wounds and ulcers’ (Group D03) and 
‘medicated dressings’ (Group D09) only one product is 
licensed and marketed. In ATC Code G, ‘Gynaecological 
Anti-Infectives and Antiseptics’, the average availability rate 
was calculated to be 70% and none of the subgroups within 
this category were considered to run the risk of availability 
problems due to having significantly higher rates of 
marketed medicines with respect to other therapeutic 
codes. The average availability rate calculated for ATC 
Code H, ‘Systemic Hormonal Preparations, excluding sex 
hormones and insulins’, was also 70% and two subgroups 
were considered at risk of availability problems, namely 
‘pancreatic hormones’ (Group H04) and ‘products for 
calcium homeostasis’ (Group H05), where for both groups 
only two products are licensed and marketed in Malta.
For ATC Code J, ‘Anti-Infectives for Systemic Use’, the 
average availability rate was calculated to be 57% and none 
of the products in this category were considered to be at 
risk of availability problems due to having significantly 
higher rates of marketed medicines with respect to other 
therapeutic codes. In ATC Code L, ‘Antineoplastic and 
Immunomodulating Agents’, the average availability rate 
of licensed medicines was 61% and no therapeutic groups 
in this category were considered to be at risk of availability 
problems. In ATC Code M, ‘Musculoskeletal System’, an 
average availability rate of 65% was noted for licensed 
medicines and only Group M09 ‘other drugs for the 
disorders of the musculoskeletal system’ was considered 
to have an availability risk since only one product is placed 
on the local market.
An average availability rate of 66% was recorded for ATC 
Code N, ‘Nervous System’ whereas the highest recorded 
availability rate (78%) for licensed medicines was that 
for ATC Code P, ‘Antiparasitic Products, Insecticides and 
Repellents’. Group P02, ‘antihelminthics’ was considered to 
be subject to an availability threat as only two products are 
licensed and marketed. For ATC code R, ‘Respiratory System’, 
an average availability rate of 61% was recorded for licensed 
On average 62% of the products authorised in 
the Malta Medicines List are subsequently placed 
on the market and made available to patients 
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medicines and no therapeutic groups in this category 
were considered to be at risk of availability problems. The 
availability rate for ATC code S, ‘Sensory Organs’, was higher 
at 67% and Group S03, ‘ophthalmological and ontological 
preparations’, was identified as being subject to availability 
risk as only one product is licensed and marketed.
For ATC Code V ‘Various’, the average availability rate of 
licensed medicines was 48%. A number of subgroups 
within this therapeutic group were considered to be at 
risk of availability issues, namely Group V01 ‘allergens’, 
Group V04 ‘diagnostic agents’ and Group V07 ‘all other 
non-therapeutic products’, where no products in these 
groups are available locally despite some products being 
authorised. No products are licensed for Group V20, 
‘surgical dressings’ and only one product is available on 
the market for Group V06, ‘general nutrients’.
The general trend observed for all ATC codes was that the 
lowest rates of availability were recorded for authorisations 
made via Article 126(a) of Directive 2001/83/EC.2 This could 
be attributed to the fact that several authorisations made 
via this route are submitted with the intention of placing 
the product in question on the national government 
formulary list. This is done through submission of an 
application in the Government tender process and if the 
marketing authorisation holder is not awarded the tender, 
the applicant may decide that it is not feasible to place the 
product on the Maltese market. 
Discussion
Smaller EU member states share some common and general 
availability problems. These countries generally do not have 
a local research and development based pharmaceutical 
industry and this, together with the fact that they are 
considered economically unattractive countries, may 
deter their inclusion as reference or concerned member 
states in mutual recognition or decentralised procedures. 
Moreover, although smaller member states are selected in 
these procedures, the launch of the product on the local 
market may not occur post-authorisation for a number of 
reasons, such as labelling in the national language.1,3
The size of the market and its national language are closely 
related. Article 63 of Directive 2001/83/EC specifies the 
requirement of having the labelling and package leaflet 
translated into a country’s national language. While this 
is not considered to be a problem for larger markets, 
it may be thought to unfeasible for smaller markets. 
Moreover, pharmaceutical companies may not be willing 
to accept the extra costs involved, such as setting up of 
a pharmacovigilance network for markets that cannot 
sustain profitability.
Repackaging facilities are easily available in all member 
states and the packaging site in charge of the repackaging 
operation should be registered in the marketing 
authorisation application and should perform the 
activities in accordance to GMP requirements. However, 
some marketing authorisation holders may refuse to use 
them either since these may incur a comparatively higher 
additional cost or potentially due to a company’s policy 
that prohibits the handling of the pharmaceutical product 
by third parties.  Overlabelling or affixing stickers with a 
different language on packaging may decrease such costs, 
however this is only applicable for products authorised via 
parallel distribution or for an emergency situation, such as 
a product supply shortage.
The introduction of country-specific information in labelling 
or product information, such as blue-box requirements, 
may decrease the motivation of a pharmaceutical company 
to make its product available on a small market. In an effort 
to counteract this, Malta has not introduced any such blue-
box requirements to eliminate this burden on marketing 
authorisation holders.
The general trend observed for all ATC codes was that  
the lowest rates of availability were recorded for authorisations  
made via Article 126(a) of Directive 2001/83/EC
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Unavailability of medicinal products has been identified 
as a problem and a priority issue, particularly for member 
states with small markets such as Malta
Conclusion
Unavailability of medicinal products has been identified 
as a problem and a priority issue, particularly for member 
states with small markets such as Malta. The potential 
detrimental effect that this may have on public health 
can sometimes be overlooked and health needs and 
requirements of all citizens from all member states within 
the EU need to be considered and protected. This is not 
always compatible with the needs and requirements of the 
pharmaceutical industry when applicants are to choose 
suitable markets for their products. Initiatives have been 
launched to improve the availability situation however, 
this has not always proved effective as these initiatives are 
not accompanied by an obligation to market. The choice of 
whether products are placed on a particular market should 
not depend solely on business feasibility and appropriate 
solutions to this problem can only be achieved through 
discussion and collaboration at high level between the EC, 
member states and stakeholders.  
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